Allogene Therapeutics Inc

NASDAQ:ALLO   3:59:46 PM EDT
28.58
+1.08 (+3.93%)
Products, Strategic Combinations

Allogene, Overland Form JV In Greater China To Develop, Commercialize AlloCAR T Cell Therapies

Published: 12/15/2020 13:40 GMT
Allogene Therapeutics Inc (ALLO) - Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize Allocar T™ Cell Therapies.
Allogene Therapeutics Inc - Overland to Invest $117 Million in Capital, Which Includes an Upfront Payment to Allogene.
Allogene Therapeutics Inc - Allogene Overland Will Receive Exclusive License to Allocar T Candidates Directed at Four Targets.
Allogene Therapeutics Inc - Overland and Allogene Are Sole Equity Holders in Allogene Overland.
Allogene Therapeutics Inc - Allogene Will Be Eligible to Receive a Milestone Payment per Product for Each First Regulatory Approval in China.